{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T10:27:19Z","timestamp":1775471239130,"version":"3.50.1"},"reference-count":68,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The use of topical and intralesional immunotherapy in the treatment of cutaneous malignant neoplasia in sensitive areas such as the lips and eyelids is discussed. Surgery may not be feasible or may result in deformities in these areas, making alternative treatment options necessary. A narrative literature review was conducted using MEDLINE (PubMed) as the main literature database, collecting available evidence of experiences with various topical and intralesional therapies in the aforementioned anatomical locations, ranging from case reports to clinical trials. The clearance rates and potential adverse reactions of therapeutic options such as imiquimod 5%, 5-fluorouracil (5-FU), photodynamic therapy (PDT), ingenol mebutate (IM), diclofenac, intralesional methotrexate, and interferon are reviewed. Although limited by their heterogeneity and the scarcity of clinical trials, these studies point towards promising response rates and minimal adverse effects, making these treatments viable options in selected cases.<\/jats:p>","DOI":"10.3390\/cancers15205018","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T08:10:19Z","timestamp":1697530219000},"page":"5018","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Topical and Intralesional Immunotherapy for the Management of Skin Cancer in Special Locations: Lips and Eyelids"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6829-9414","authenticated-orcid":false,"given":"Cecilia","family":"Buj\u00e1n Bonino","sequence":"first","affiliation":[{"name":"Department of Dermatology, University Hospital of Santiago de Compostela, 36001 Santiago de Compostela, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Rodr\u00edguez-Blanco","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of Santiago de Compostela, 36001 Santiago de Compostela, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolores","family":"S\u00e1nchez-Aguilar Rojas","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of Santiago de Compostela, 36001 Santiago de Compostela, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo A.","family":"V\u00e1zquez Veiga","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of Santiago de Compostela, 36001 Santiago de Compostela, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9373-7826","authenticated-orcid":false,"given":"\u00c1ngeles","family":"Fl\u00f3rez","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of Pontevedra, 36162 Pontevedra, Spain"},{"name":"DIPO Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), Servizo Galego de Sa\u00fade\u2014Universidade de Vigo (SERGAS\u2014UVIGO), 36213 Vigo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/ced.13763","article-title":"Ingenol Mebutate versus Imiquimod versus Diclofenac for Actinic Cheilitis: A 6-Month Follow-up Clinical Study","volume":"44","year":"2019","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e12613","DOI":"10.1111\/dth.12613","article-title":"Dermoscopy and Reflectance Confocal Microscopy for Monitoring the Treatment of Actinic Cheilitis with Ingenol Mebutate Gel: Report of Three Cases","volume":"31","author":"Benati","year":"2018","journal-title":"Dermatol. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaad.2011.09.040","article-title":"Solar Cheilosis: An Ominous Precursor: Part I. Diagnostic Insights","volume":"66","author":"Jadotte","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Pentangelo, G., Nistic\u00f2, S.P., Provenzano, E., Cisale, G.Y., and Bennardo, L. (2021). Topical 5% Imiquimod Sequential to Surgery for HPV-Related Squamous Cell Carcinoma of the Lip. Medicina, 57.","DOI":"10.3390\/medicina57060563"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/jocd.14118","article-title":"Use of Topical Anti-Inflammatory and Antineoplastic Agents in the Treatment of Young-Aged Actinic Cheilitis: A Systematic Review","volume":"21","author":"Medeiros","year":"2022","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s00784-019-02895-z","article-title":"Treatment of Actinic Cheilitis: A Systematic Review","volume":"23","author":"Salgueiro","year":"2019","journal-title":"Clin. Oral Investig."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2340\/00015555-3237","article-title":"Actinic Cheilitis: Analysis of Clinical Subtypes, Risk Factors and Associated Signs of Actinic Damage","volume":"99","author":"Paradela","year":"2019","journal-title":"Acta Derm. Venereol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"970","DOI":"10.2340\/00015555-3014","article-title":"Actinic Cheilitis Prevalence and Risk Factors: A Cross-Sectional, Multicentre Study in a Population Aged 45 Years and Over in North-West Spain","volume":"98","author":"Paradela","year":"2018","journal-title":"Acta Derm. Venereol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Bakirtzi, K., Papadimitriou, I., Andreadis, D., and Sotiriou, E. (2021). Treatment Options and Post-Treatment Malignant Transformation Rate of Actinic Cheilitis: A Systematic Review. Cancers, 13.","DOI":"10.3390\/cancers13133354"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jaad.2019.07.106","article-title":"Treatments of Actinic Cheilitis: A Systematic Review of the Literature","volume":"83","author":"Lai","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_11","first-page":"1099","article-title":"Treatment of Actinic Keratosis: A Systematic Review","volume":"315","author":"Worley","year":"2022","journal-title":"Arch. Dermatol. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"20569","DOI":"10.1007\/s11356-018-2426-z","article-title":"Immune Consequences Induced by Photodynamic Therapy in Non-Melanoma Skin Cancers: A Review","volume":"25","author":"Yu","year":"2018","journal-title":"Environ. Sci. Pollut. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s00403-020-02069-y","article-title":"Daylight Photodynamic Therapy for the Management of Actinic Cheilitis","volume":"312","author":"Andreadis","year":"2020","journal-title":"Arch. Dermatol. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/phpp.12415","article-title":"Daylight Photodynamic Therapy for the Treatment of Actinic Cheilitis","volume":"35","author":"Levi","year":"2019","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/bjd.13542","article-title":"Efficacy of Ablative Fractional Laser-Assisted Photodynamic Therapy for the Treatment of Actinic Cheilitis: 12-Month Follow-up Results of a Prospective, Randomized, Comparative Trial","volume":"173","author":"Choi","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/j.1365-2133.2011.10478.x","article-title":"Sequential Use of Photodynamic Therapy and Imiquimod 5% Cream for the Treatment of Actinic Cheilitis: A 12-Month Follow-up Study","volume":"165","author":"Sotiriou","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/09546634.2016.1188196","article-title":"Management of Actinic Cheilitis Using Ingenol Mebutate Gel: A Report of Seven Cases","volume":"28","author":"Batalla","year":"2017","journal-title":"J. Dermatol. Treat."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1080\/09546634.2020.1724865","article-title":"Ingenol Mebutate Treatment for Actinic Cheilitis: Clinical, Histopathological and P53 Profile of 14 Cases","volume":"32","author":"Dellatorre","year":"2021","journal-title":"J. Dermatol. Treat."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"102043","DOI":"10.1016\/j.pdpdt.2020.102043","article-title":"Surgery Sequential with 5-Aminolevulinic Acid Photodynamic Therapy for Lip Squamous Cell Carcinoma: Two Cases Reports","volume":"32","author":"Yan","year":"2020","journal-title":"Photodiagnosis Photodyn. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"102857","DOI":"10.1016\/j.pdpdt.2022.102857","article-title":"Photodynamic Therapy of Intravenous Injection Combined with Intratumoral Administration of Photosensitizer in Squamous Cell Carcinoma","volume":"38","author":"Wang","year":"2022","journal-title":"Photodiagnosis Photodyn. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"101798","DOI":"10.1016\/j.pdpdt.2020.101798","article-title":"Photodynamic Therapy for Keratoacanthoma on the Upper Lip","volume":"30","author":"Liang","year":"2020","journal-title":"Photodiagnosis Photodyn. Ther."},{"key":"ref_22","first-page":"331","article-title":"Photodynamic Therapy for the Treatment of Microinvasive Squamous Cell Carcinoma of the Lower Lip: A Case Report","volume":"150","author":"Fargnoli","year":"2015","journal-title":"G. Ital. Di Dermatol. E Venereol. Organo Uff. Soc. Ital. Di Dermatol. E Sifilogr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jdcr.2017.04.008","article-title":"Topical Imiquimod for the Palliative Treatment of Recurrent Oral Squamous Cell Carcinoma","volume":"3","author":"Wester","year":"2017","journal-title":"JAAD Case Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/jdv.13266","article-title":"Neoadjuvant Intralesional Methotrexate in Cutaneous Squamous Cell Carcinoma: A Comparative Cohort Study","volume":"30","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/ajd.12946","article-title":"Neoadjuvant Intralesional Methotrexate in Squamous Cell Carcinoma of the Lip","volume":"60","year":"2019","journal-title":"Australas. J. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/hed.23408","article-title":"Continuous Intra-Arterial Chemotherapy for Downstaging Locally Advanced Oral Commissure Carcinoma","volume":"36","author":"Wu","year":"2014","journal-title":"Head Neck"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1684\/ejd.2016.2957","article-title":"Near-Infrared Image-Guided Super-Selective Intra-Arterial Infusion of High-Dose Cisplatin for Squamous Cell Carcinoma on the Lower Lip","volume":"27","author":"Yokota","year":"2017","journal-title":"Eur. J. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.survophthal.2015.05.004","article-title":"Clinical Use of Photodynamic Therapy in Ocular Tumors","volume":"60","author":"Cerman","year":"2015","journal-title":"Surv. Ophthalmol."},{"key":"ref_29","first-page":"21","article-title":"Therapy Failure and Resistance Mechanism in Eyelid and Ocular Surface Tumors","volume":"30","author":"Ju","year":"2022","journal-title":"Neurosignals"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"De Macedo, E.M.S., Carneiro, R.C., De Lima, P.P., Silva, B.G., and Matayoshi, S. (2015). Imiquimod Cream Efficacy in the Treatment of Periocular Nodular Basal Cell Carcinoma: A Non-Randomized Trial. BMC Ophthalmol., 15.","DOI":"10.1186\/s12886-015-0024-0"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00417-010-1526-3","article-title":"Long-Term Outcome after Treatment with 5% Topical Imiquimod Cream in Patients with Basal Cell Carcinoma of the Eyelids","volume":"249","author":"Prokosch","year":"2011","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/bjo.2010.193078","article-title":"Comparison of Imiquimod 5% Cream versus Radiotherapy as Treatment for Eyelid Basal Cell Carcinoma","volume":"95","author":"Idoipe","year":"2011","journal-title":"Br. J. Ophthalmol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/IOP.0b013e3181b8dd71","article-title":"Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma","volume":"26","author":"Carneiro","year":"2010","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1755-3768.2007.00896.x","article-title":"Imiquimod in the Treatment of Eyelid Basal Cell Carcinoma","volume":"85","author":"Kaarniranta","year":"2007","journal-title":"Acta Ophthalmol. Scand."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.ajo.2005.06.057","article-title":"Immunotherapy with Imiquimod 5% Cream for Eyelid Nodular Basal Cell Carcinoma","volume":"140","author":"Blasi","year":"2005","journal-title":"Am. J. Ophthalmol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00417-007-0561-1","article-title":"Treatment of Basal Cell Carcinoma of the Eyelids with 5% Topical Imiquimod: A 3-Year Follow-up Study","volume":"245","author":"Choontanom","year":"2007","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/01676830903294909","article-title":"The Use of Imiquimod in the Treatment of Periocular Tumours","volume":"29","author":"Ross","year":"2010","journal-title":"Orbit"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/s41433-022-02165-5","article-title":"Treatment of Periocular Lentigo Maligna with Topical 5% Imiquimod: A Review","volume":"37","author":"Neumann","year":"2023","journal-title":"Eye"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S1470-2045(13)70143-8","article-title":"Photodynamic Therapy versus Topical Imiquimod versus Topical Fluorouracil for Treatment of Superficial Basal-Cell Carcinoma: A Single Blind, Non-Inferiority, Randomised Controlled Trial","volume":"14","author":"Arits","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1177\/11206721211035614","article-title":"Long-Term Efficacy and Safety of Imiquimod 5% and Fluorouracil 1% Creams in Medical Monotherapy of Complex Eyelid Basal Cell Carcinomas","volume":"32","author":"Singh","year":"2022","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_41","first-page":"944","article-title":"Photodynamic Therapy for Tumors on the Eyelid Margins","volume":"145","author":"Wulf","year":"2009","journal-title":"Arch. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/j.1468-3083.2009.03195.x","article-title":"Photodynamic Therapy of Eyelid Basal Cell Carcinoma","volume":"23","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1034\/j.1600-0420.1999.770213.x","article-title":"Photodynamic Therapy Utilising Topical Delta-Aminolevulinic Acid in Non-Melanoma Skin Malignancies of the Eyelid and the Periocular Skin","volume":"77","author":"Wang","year":"1999","journal-title":"Acta Ophthalmol. Scand."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.pdpdt.2019.06.016","article-title":"Ocular Preservation through Limited Tumor Excision Combined with ALA-PDT in Patients with Periocular Basal Cell Carcinoma","volume":"27","author":"Li","year":"2019","journal-title":"Photodiagnosis Photodyn. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/IOP.0b013e31819a4404","article-title":"Photodynamic Therapy Using Methyl Aminolevulinate Acid in Eyelid Basal Cell Carcinoma: A 5-Year Follow-up Study","volume":"25","author":"Puccioni","year":"2009","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"ref_46","first-page":"207","article-title":"Interferon Eyedrops in the Treatment of Basal Cell Carcinoma of the Eyelid","volume":"105","year":"2014","journal-title":"Actas Dermosifiliogr."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1034\/j.1600-0420.2002.800623_3.x","article-title":"The Role of Interferon Alpha 2b as an Adjunctive Treatment in the Management of Aggressive Basal Cell Carcinoma of the Eyelids","volume":"80","author":"Fenton","year":"2002","journal-title":"Acta Ophthalmol. Scand."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"410","DOI":"10.4103\/0974-9233.167822","article-title":"Intralesional Bleomycin as an Adjunct Therapeutic Modality in Eyelid and Extraocular Malignancies and Tumors","volume":"22","author":"Meyer","year":"2015","journal-title":"Middle East Afr. J. Ophthalmol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1038\/s41598-019-41026-2","article-title":"Electrochemotherapy in the Treatment of Locally Advanced or Recurrent Eyelid-Periocular Basal Cell Carcinomas","volume":"9","author":"Kis","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/ICU.0b013e328356ad55","article-title":"Topical Therapies for Periorbital Cutaneous Malignancies: Indications and Treatment Regimens","volume":"23","author":"Sullivan","year":"2012","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/IOP.0b013e3182467c68","article-title":"Topical 5-Fluorouracil for the Treatment of Periocular Actinic Keratosis and Low-Grade Squamous Malignancy","volume":"28","author":"Couch","year":"2012","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/j.1442-9071.2011.02564.x","article-title":"Eyelid Squamous Cell Carcinoma in Situ Treated with Topical 5-Fluorouracil","volume":"39","author":"Sharkawi","year":"2011","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1136\/bjo.2009.178202","article-title":"The Ophthalmic Side-Effects of Imiquimod Therapy in the Management of Periocular Skin Lesions","volume":"95","author":"Cannon","year":"2011","journal-title":"Br. J. Ophthalmol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e15800","DOI":"10.1111\/dth.15800","article-title":"Complete Response of Locally Advanced Cutaneous Squamous Cell Carcinoma of the Eyelid to Topical Imiquimod 3.75","volume":"35","author":"Toso","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_55","first-page":"938","article-title":"Photodynamic Therapy as a Response to the Challenge of Treating Actinic Keratosis in the Eyelid Area","volume":"103","year":"2012","journal-title":"Actas Dermosifiliogr."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1179\/joc.2004.16.3.306","article-title":"Squamous Cell Carcinoma of the Eyelid Treated with Photodynamic Therapy","volume":"16","author":"Rossi","year":"2004","journal-title":"J. Chemother."},{"key":"ref_57","unstructured":"Sunohara, M.O.T. (2023, June 01). Dye Laser Photodynamic Therapy for Bowen\u2019s Disease in a Patient with Epidermodysplasia Verruciformis-PubMed, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/23610850\/."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/j.1365-4632.2008.03720.x","article-title":"Photodynamic Therapy for the Treatment of in Situ Squamous Cell Carcinoma of the Left Eyelid","volume":"47","author":"Calista","year":"2008","journal-title":"Int. J. Dermatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IOP.0b013e318224ae9b","article-title":"Topical Diclofenac Gel for the Management of Periocular Actinic Keratosis","volume":"28","author":"Batra","year":"2012","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"ref_60","first-page":"1063","article-title":"Palliative Intralesional Tumescent Methotrexate for Recurrent Locally Advanced Periocular Cutaneous Squamous Cell Carcinoma","volume":"18","author":"Carriere","year":"2020","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1136\/bjo.86.8.932","article-title":"Successful Treatment of Squamous Cell Carcinoma of the Lower Eyelid with Intralesional Cidofovir","volume":"86","author":"Calista","year":"2002","journal-title":"Br. J. Ophthalmol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1524-4725.1990.tb00080.x","article-title":"Aggressive Keratoacanthoma of the Eyelid: \u201cMalignant\u201d Keratoacanthoma or Squamous Cell Carcinoma?","volume":"16","author":"Requena","year":"1990","journal-title":"J. Dermatol. Surg. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1016\/j.ophtha.2010.03.049","article-title":"Topical Imiquimod for Periocular Lentigo Maligna","volume":"117","author":"Demirci","year":"2010","journal-title":"Ophthalmology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/jdv.14085","article-title":"A Systematic Review on the Role of Imiquimod in Lentigo Maligna and Lentigo Maligna Melanoma: Need for Standardization of Treatment Schedule and Outcome Measures","volume":"31","author":"Tio","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s13555-021-00667-w","article-title":"Lentigo Maligna on a Difficult Location of the Face Treated with 5% Imiquimod: A Case Report of 2-Year Follow-Up","volume":"12","author":"Czuwara","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_66","unstructured":"Cornejo, P., Vanaclocha, F., Polimon, I., and Del R\u00edo, R. (2023, May 22). Intralesional Interferon Treatment of Lentigo Maligna|Dermatology|JAMA Dermatology|JAMA Network. Available online: https:\/\/jamanetwork-com.mergullador.sergas.es\/journals\/jamadermatology\/fullarticle\/189990."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1001\/archderm.136.11.1415","article-title":"Intralesional Interferon Alfa for Treatment of Recurrent Lentigo Maligna of the Eyelid in a Patient with Primary Acquired Melanosis","volume":"136","author":"Carucci","year":"2000","journal-title":"Arch. Dermatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1984677","DOI":"10.1080\/2162402X.2021.1984677","article-title":"Trial watch: Intratumoral immunotherapy","volume":"10","author":"Humeau","year":"2021","journal-title":"Oncoimmunology"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/20\/5018\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:08:05Z","timestamp":1760130485000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/20\/5018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,17]]},"references-count":68,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["cancers15205018"],"URL":"https:\/\/doi.org\/10.3390\/cancers15205018","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,17]]}}}